Quick Answer
Indaptus Therapeutics, Inc. reported Net Income of -$20.85 million for fiscal year 2025.
Indaptus Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$20.85M | -38.8% |
| 2024 | -$15.02M | +2.6% |
| 2023 | -$15.42M | -7.7% |
| 2022 | -$14.32M | -85.7% |
| 2021 | -$7.71M | -115.2% |
| 2020 | -$3.58M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.98M | +3.1% | +43.1% |
| June 30, 2025 | -$5.23M | -30.2% | -15.4% |
| March 31, 2025 | -$4.53M | -19.1% | -47.7% |
| September 30, 2024 | -$3.07M | +21.8% | +23.6% |
| June 30, 2024 | -$4.02M | -23.7% | -5.5% |
| March 31, 2024 | -$3.81M | +10.5% | +3.0% |
| September 30, 2023 | -$3.92M | -13.2% | -20.9% |
| June 30, 2023 | -$3.25M | +15.4% | +23.7% |
- Indaptus Therapeutics, Inc. showed a decrease of -38.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Indaptus Therapeutics, Inc.’s net income has declined by 481.7% (from -$3.58 million to -$20.85 million).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: